Rheumatology – pharma.markets

Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile

26/06/2020 MaP 0

• EMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis • CHMP opinion based on two Phase […]

Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

20/06/2020 MaP 0

• FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of […]

Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis

07/06/2020 MaP 0

• Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to […]